Diabetic Nephropathy Market 2022
Electromagnetic radiation inclusive of infrared radiation, photoacoustic or thermal spectroscopy, millimetre waves let smoother remote measurement of glucose concentration in blood, that too, either continuously or punctually, that too, without stinging. There are also smart insulin and bioartificial pancreas being incorporated for treating insulin resistance. Type I diabetes is expected to be treated through immunotherapy. Intestinal microbiota has proved as a strong force against Type II diabetes. This would be the behaviour of the diabetes treatment market in future, thereby being resplendent for diabetic patients.
According to a new market report published by Persistence Market Research “Global Market Study on Diabetic Nephropathy Market – Asia to Witness Highest Growth by 2022,”.The global diabetic nephropathy market was valued at USD 2,262.2 million in 2014 and is expected to grow at a CAGR of 5.6% from 2014 to 2022, to reach an expected value of USD 3,145.9 million in 2022.
Request For Free Sample Report of Diabetic Nephropathy Market @ https://www.persistencemarketresearch.com/samples/3594
Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Globally, the diabetic nephropathy market is witnessing significant growth due to increasing prevalence of diabetes and obesity in different regions of the world.
In addition, increasing R&D investments in drug discovery and development and raising awareness about diabetes and kidney-related disorders are also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. The global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020.
In North America, various government programs are spreading awareness about diabetes and related renal complications. For instance, the National Kidney Disease Education Program, one of the major programs organized by the U.S. government, for increasing awareness about the various kidney diseases. In addition, the number of diabetic patients are also increasing in the region; according to the SciELO Public Health, approximately 35 million people were affected with diabetes mellitus in 2000 and this number is expected to reach 64 million by 2025 in North America.
In Europe, rise in healthcare expenditure for diabetes treatment and increasing prevalence of diabetes in the various part of Europe is boosting the growth of the European diabetic nephropathy market. According to IDF, approximately 55.4 million people had diabetes in 2010 and the number is expected to reach 66.5 million by 2030 in Europe. According to the IDF, healthcare expenditure for diabetes treatment was approximately USD 105.5 billion in 2010 and is expected to reach USD 124.6 billion by 2030 in Europe.
For critical insights on this market, request for customization here@ https://www.persistencemarketresearch.com/request-customization/3594
Asia represents the fastest growing region in the diabetic nephropathy market due to the rise in a diabetic population in various countries such as Japan and the Southeast Asian countries. According to the International Diabetes Federation (IDF), developing countries, such as India and China, are expected to have the highest number of diabetes mellitus patients compared to developed countries, such as the U.S. and Germany.
Sanofi is one of the leading players in the diabetic nephropathy market. Other major players in diabetic nephropathy market include Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Novartis AG, Pfizer, Inc., Abbott Laboratories, AbbVie, Inc., Bayer AG, Merck & Co., Inc., Bayer AG and Reata Pharmaceuticals, Inc.
Diabetic nephropathy market, by model of treatment
- Disease Modifying Therapies
- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Receptor Blockers
- Diuretics
- Calcium Channel Blockers
- Renin Inhibitors
- Connective Tissue Growth Factor Inhibitors
- Antioxidant Inflammation Modulator
- Monocyte Chemoattractant Proteins Inhibitor
- Endothelin-A Receptor Antagonist
- G Protein-Coupled Receptors
Diabetic nephropathy market, by geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Asia
- Japan
- China
- India
- Rest of the World (RoW)
Buy The Complete Report to read the analysed strategies adopted by the top vendors either to retain or gain market share@ https://www.persistencemarketresearch.com/checkout/3594
Key Questions Answered in This Report.
- What will the Market growth rate in Future?
- What are the key factors driving the global Market?
- Who are the key manufacturers in Market space?
- What are the opportunities and threats faced by the vendors in the global industry?
- What are sales, revenue, and price analysis by regions of industry?
Other Trending Reports:
- X-ray Photoelectron Spectroscopy Market
- Bariatric Surgery Devices Market
- Advanced Medical Nutrition Market
- Sds Poly Acrylamide Gel Electrophoresis Market
About Us
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. Th company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
US Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353